Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
April 08, 2025 16:05 ET | Source: Annexon Biosciences Oral Presentation Features…
FDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples…
Allogenica Secures 2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen Frances Biotherapy Leadership
Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen…
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader…
![Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement](https://i1.wp.com/ml-eu.globenewswire.com/media/MjU1NjVjOWEtMTBjOC00MTE0LWI0NTUtYjdlMjkzODM0MzYzLTEyMjA5NDY=/tiny/Zelluna-ASA.png?w=420&resize=420,280&ssl=1 "Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement")
Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement
March 03, 2025 10:46 ET | Source: Zelluna ASA Oslo, Norway, 03…
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell…
The debate on MSCs is over; it’s time to promote MSC therapy in practice
TIANJIN, China, Feb. 26, 2025 /PRNewswire/ -- The debate on MSCs, mesenchymal…
Bay Area Therapy Center Offers Specialized Therapy for Overcoming Communication and Relationship Issues in San Francisco
SAN FRANCISCO, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Bay Area Therapy Center…
Bay Area Cognitive Behavioral Therapy Center Expands Treatment Offerings with Acceptance and Commitment Therapy
SAN FRANCISCO, Feb. 22, 2025 (GLOBE NEWSWIRE) -- The Bay Area Cognitive…